JAN 03, 2017 08:30 PM PST

Dendritic Cell Vaccines Promising For Breast Cancer

WRITTEN BY: Kara Marker

A vaccine for cancer is on the horizon, although it works in a way different to what most people might consider a conventional vaccine. Using a personalized approach, scientists from the Moffitt Cancer Center are on the brink of a new treatment option for breast cancer patients.

Researchers tested the safety and efficacy of the new vaccine technology in a clinical trial with 54 women all diagnosed with early-stage breast cancer. The other quality these women shared was that their breast cancer cells expressed HER2, a protein that is overexpressed in nearly a quarter of all breast cancers and which is unfortunately linked to cases of a particularly aggressive cancer and a poor prognosis.

Expressing HER2 works for cancer cells because immune cells that are designed to fight tumors cannot recognize and target cancer cells as well when they display this protein on their cell surface, as if the immune system didn’t already have enough on its plate in a case of cancer.

This is where the idea came to create a vaccine of sorts, designed for dendritic cells. The vaccine helps the immune system relearn to recognize HER2, and researchers could extract dendritic cells from each breast cancer patient to cater a dendritic cell vaccine specifically to each person.

Vaccines in the clinical trial were reinjected into a lymph node, breast tumor, or both once a week for six weeks. Results showed that the treatment was well received and women experienced only low-grade toxicity, if any. Not many cancer treatments can say the same. Very few side effects occurred, with the most common being fatigue, injection site reactions, and chills.

Remarkably, researchers saw a clear immune response to the vaccine in 80 percent of evaluable patients, and all of the responses were similar despite variation of vaccine administration location.

"These results suggest that vaccines are more effective in [ductal carcinoma in situ (DCIS, an early non-invasive disease)], thereby warranting further evaluation in DCIS or other minimal disease settings, and the local regional sentinel lymph node may serve as a more meaningful immunologic endpoint," explained Brian J. Czerniecki, MD, PhD

The present study was published in the journal Clinical Cancer Research.

Source: Moffitt Cancer Center

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAY 04, 2018
Clinical & Molecular DX
MAY 04, 2018
New Blood Test Detects Peanut Allergy with 98% Specificity
A new blood test trumps traditional diagnostic methods for determining peanut allergy, the most common allergy for children. From the Medical Research Coun...
MAY 07, 2018
Immunology
MAY 07, 2018
Breast Milk: An Important Source of Protective Immune Cells
For the first time, scientists have identified innate lymphoid cells (ILCs) among the arsenal of protective cells transferred to newborn babies via breast...
MAY 17, 2018
Immunology
MAY 17, 2018
Epigenetic Similarities Between Rheumatoid Arthritis and Huntington's Disease
A detailed investigation into the epigenome of rheumatoid arthritis (RA) patients revealed unexpected similarities between RA and Huntington’s diseas...
JUN 04, 2018
Immunology
JUN 04, 2018
Asthma and Flu Make A Deadly Combination
When someone with a cold or the flu also has an asthma attack, the situation can become life-threatening very quickly. From the University of Montreal, sci...
JUL 04, 2018
Drug Discovery
JUL 04, 2018
Increased Dose of Drug 'Rifampin' Effective in Eliminating Tuberculosis Bacterium
According to a randomized controlled trial, a TB drug by the name ‘Rifampin’ was seen to effectively kill TB bacteria in sputum cultures when a...
AUG 15, 2018
Immunology
AUG 15, 2018
Female vs. Male: The Immune Response
There is a genetic sexual conflict in the immune system, with females showing high variation in central genes compared to males....
Loading Comments...